The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Remdesivir for the Treatment of Covid-19 — Final Report
Open accessAbstract
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258 · cited 4×
“The trial site in South Korea received funding from the Seoul National University Hospital.”
InfluentialWang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442
Sheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,757
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · cited 3×
“There were 60 trial sites and 13 subsites in the United States (45 sites), Denmark (8), the United Kingdom (5), Greece (4), Germany (3), Korea (2), Mexico (2), Spain (2), Japan (1), and Singapore (1).”
Agostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418
Spinner, C. D., Gottlieb, R., Criner, G. J., Arribas, J. R., Cattelan, A. M., Soriano, À., Ogbuagu, O. E., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,234
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D. P., Cihlář, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 888
Cited by
Sorted by citations
Items 601–700 of 1,018
Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin
de Melo, G. D., Lazarini, F., Larrous, F., Feige, L., Kornobis, É., Levallois, S., Marchio, A., Kergoat, L., Hardy, D., Cokelaer, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114122 · Cited by 86
Juul, S., Nielsen, E. E., Feinberg, J. B., Siddiqui, F., Kamp, C. B., Barot, E., Nielsen, N., Bentzer, P., Veroniki, A. A., Thabane, L., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003293 · Cited by 85
Marked Sinus Bradycardia Associated With Remdesivir in COVID-19
Gubitosa, J. C., Kakar, P., Gerula, C. M., Nossa, H., Finkel, D. G., Wong, K. G., Khatri, M., & Ali, H. (2020) · JACC Case Reports · doi:10.1016/j.jaccas.2020.08.025 · Cited by 84
Innate lymphoid cell composition associates with COVID‐19 disease severity
García, M., Kokkinou, E., García, A. C., Parrot, T., Medina, L. M. P., Maleki, K. T., Christ, W., Varnaitė, R., Filipovic, I., Ljunggren, H., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1224 · Cited by 85
Distinctive features of severe SARS-CoV-2 pneumonia
Budinger, G. R. S., Misharin, A. V., Ridge, K. M., Singer, B. D., & Wunderink, R. G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149412 · Cited by 87
Chaisuwan, W., Phimolsiripol, Y., Chaiyaso, T., Techapun, C., Leksawasdi, N., Jantanasakulwong, K., Rachtanapun, P., Wangtueai, S., Sommano, S. R., You, S., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.772033 · Cited by 82
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Hashemian, S. M. R., Pourhanifeh, M. H., Hamblin, M. R., Shahrzad, M. K., & Mirzaei, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112517 · Cited by 84
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H., & Sivaraman, J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.004 · Cited by 83
COVID-19 in Brazil: 150,000 deaths and the Brazilian underreporting
Carvalho, T. A., Boschiero, M. N., & Marson, F. A. L. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115258 · Cited by 83
A systematic review assessing the under-representation of elderly adults in COVID-19 trials
on behalf of ESCMID Study Group for Infections in the Elderly (ESGIE), Prendki, V., Tau, N., Avni, T., Falcone, M., Huttner, A. C., Kaiser, L., Paul, M., Weissman, Y. L., & Yahav, D. (2020) · BMC Geriatrics · doi:10.1186/s12877-020-01954-5 · Cited by 84
COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?
Ombrello, M. J., & Schulert, G. S. (2021) · Translational research · doi:10.1016/j.trsl.2021.03.002 · Cited by 84
The COVID-19 Vaccines: Recent Development, Challenges and Prospects
Yan, Y., Pang, Y. X., Lyu, Z., Wang, R., Wu, X., You, C., Zhao, H., Manickam, S., Lester, E. H., Wu, T., et al. (2021) · Vaccines · doi:10.3390/vaccines9040349 · Cited by 87
Vitamin A Plasma Levels in COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
Tepasse, P., Vollenberg, R., Fobker, M., Kabar, I., Schmidt, H., Meier, J. A., Nowacki, T. M., & Hüsing‐Kabar, A. (2021) · Nutrients · doi:10.3390/nu13072173 · Cited by 85
Hoogenboom, W. S., Pham, A., Anand, H., Fleysher, R., Buczek, A., Soby, S., Mirhaji, P., Yee, J., & Duong, T. Q. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100041 · Cited by 83
Amara, A., Penchala, S. D., Else, L., Hale, C., Fitzgerald, R. J., Walker, L. E., Lyons, R., Fletcher, T. E., & Khoo, S. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114356 · Cited by 83
Wu, M., Liu, F., Sun, J., Li, X., He, X.-Y., Zheng, H., Pei, R., Sun, H., Zhou, Y.-H., Yan, Q., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00849-0 · Cited by 86
Dufour, J., Marjot, T., Becchetti, C., & Tilg, H. (2022) · Gut · doi:10.1136/gutjnl-2021-326792 · Cited by 89
COVID-19 drug discovery and treatment options
Chan, J. F., Yuan, S., Chu, H., Sridhar, S., & Yuen, K. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01036-y · Cited by 92
“These data facilitated its rapid repositioning as the first US Food and Drug Administration (FDA)-approved antiviral drug for COVID-19 after promising in vitro, in vivo and clinical evaluation data were obtained 18,101,140 .”
Stamm, P., Sagoschen, I., Weise, K., Plachter, B., Münzel, T., Gori, T., & Vosseler, M. (2021) · Medical Microbiology and Immunology · doi:10.1007/s00430-021-00720-7 · Cited by 82
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
Jordan, S. C., Zakowski, P. C., Tran, H. P. N., Smith, E. A., Gaultier, C., Marks, G., Zabner, R., Lowenstein, H., Oft, J. R., Bluen, B. E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa812 · Cited by 83
Hu, K., Wang, M. E., Zhao, Y., Zhang, Y., Wang, T., Zheng, Z., Li, X., Zeng, S., Zhao, D., Li, H., et al. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00258-7 · Cited by 92
Hultcrantz, M. L., Richter, J. R., Rosenbaum, C. A., Patel, D., Smith, E. L., Korde, N., Lu, S. X., Mailankody, S., Shah, U. A., Lesokhin, A. M., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0102 · Cited by 91
SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells
Cannalire, R., Stefanelli, I., Cerchia, C., Beccari, A. R., Pelliccia, S., & Summa, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165707 · Cited by 84
Marian, A. J. (2020) · Cardiovascular Pathology · doi:10.1016/j.carpath.2020.107278 · Cited by 88
Simon, H., Sakano, T. M. S., Rodrigues, R. M., Eisencraft, A. P., Carvalho, V. E. D. L., Schvartsman, C., & Reis, A. G. (2020) · Jornal de Pediatria · doi:10.1016/j.jped.2020.08.004 · Cited by 82
Bikdeli, B., Talasaz, A. H., Rashidi, F., Sharif-Kashani, B., Farrokhpour, M., Bakhshandeh, H., Sezavar, S. H., Dabbagh, A., Beigmohammadi, M. T., Payandemehr, P., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.027 · Cited by 84
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care
Saviano, A., Wrensch, F., Ghany, M. G., & Baumert, T. F. (2020) · Hepatology · doi:10.1002/hep.31684 · Cited by 82
Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection
Inaba, M., Higashimoto, Y., Toyama, Y., Horiguchi, T., Hibino, M., Iwata, M., Imaizumi, K., & Doi, Y. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.018 · Cited by 82
Rathore, S. S., Rojas, G. A., Sondhi, M., Pothuru, S., Pydi, R., Kancherla, N., Singh, R., Ahmed, N. K., Shah, J., Tousif, S., et al. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14470 · Cited by 83
An update of anti-viral treatment of COVID-19
Yavuz, S. Ş., & Celikyurt, I. K. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2106-250 · Cited by 88
Jone, P.-N., John, A., Oster, M. E., Allen, K., Tremoulet, A. H., Saarel, E. V., Lambert, L. M., Miyamoto, S. D., & de Ferranti, S. D. (2022) · Circulation · doi:10.1161/cir.0000000000001064 · Cited by 87
Structural basis for substrate selection by the SARS-CoV-2 replicase
Malone, B. F., Perry, J. K., Olinares, P. D. B., Lee, H. W., Chen, J., Appleby, T. C., Feng, J. Y., Bilello, J. P., Ng, H., Sotiris, J., et al. (2023) · Nature · doi:10.1038/s41586-022-05664-3 · Cited by 86
Four months into the COVID-19 pandemic, Sweden’s prized herd immunity is nowhere in sight
Orlowski, E. J. W., & Goldsmith, D. J. A. (2020) · Journal of the Royal Society of Medicine · doi:10.1177/0141076820945282 · Cited by 89
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
Simonis, A., Theobald, S. J., Fätkenheuer, G., Rybniker, J., & Malin, J. J. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202013105 · Cited by 87
Hassanein, M., Radhakrishnan, Y., Sedor, J. R., Vachharajani, T. J., Vachharajani, V., Augustine, J. J., Demirjian, S. G., & Thomas, G. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.20072 · Cited by 83
Wang, Z., Zheutlin, A. B., Kao, Y.-H., Ayers, K. L., Gross, S. J., Kovatch, P., Nirenberg, S., Charney, A. W., Nadkarni, G. N., Freitas, J. K. D., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040441 · Cited by 79
Piscoya, A., Ng-Sueng, L. F., del Riego, A. P., Cerna-Viacava, R., Pasupuleti, V., Roman, Y. M., Thota, P., White, C. M., & Hernández, A. V. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243705 · Cited by 81
Padhi, A. K., Seal, A., Khan, J. M., Ahamed, M., & Tripathi, T. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173836 · Cited by 84
Major Update: Remdesivir for Adults With COVID-19
Kaka, A. S., MacDonald, R. H., Greer, N. L., Vela, K., Duan‐Porter, W., Obley, A. J., & Wilt, T. J. (2021) · Annals of Internal Medicine · doi:10.7326/m20-8148 · Cited by 81
Lai, C., Chen, C., Wang, C., Chen, K.-H., Wang, Y., & Hsueh, P. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab093 · Cited by 81
Ning, Q., Wu, D., Wang, X., Xi, D., Chen, T., Chen, G., Wang, H., Lü, H., Wang, M., Zhu, L., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00907-1 · Cited by 86
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C., Gervais, A., Voyer, T. L., Bizien, L., Zamecnik, C. R., Philippot, Q., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8966 · Cited by 86
Trottier, C. A., Wong, B., Kohli, R., Boomsma, C., Magro, F., Kher, S., Anderlind, C., & Golan, Y. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac847 · Cited by 82
Shahbaznejad, L., Davoudi, A., Eslami, G., Markowitz, J. S., Navaeifar, M. R., Hosseinzadeh, F., Movahedi, F. S., & Rezai, M. S. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.007 · Cited by 80
Andrew, M., & Jayaraman, G. (2021) · Carbohydrate Research · doi:10.1016/j.carres.2021.108326 · Cited by 80
Schlapbach, L. J., Andre, M. C., Grazioli, S., Schöbi, N., Ritz, N., Aebi, C., Agyeman, P., Albisetti, M., Bailey, D. G. N., Berger, C., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.667507 · Cited by 80
Zeng, J., Weissmann, F., Bertolin, A. P., Posse, V., Canal, B., Ulferts, R., Wu, M., Harvey, R., Hussain, S., Milligan, J. C., et al. (2021) · Biochemical Journal · doi:10.1042/bcj20210201 · Cited by 81
Santos, A., de Sousa, L. L., Calça, R., Lima, A., Nascimento, C., Jorge, C., Adragão, T., Bruges, M., Peres, S., & Weigert, A. (2021) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2021-0164 · Cited by 80
Marjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84
“2% in the placebo group.(150) There were no differences in clinical outcomes observed between those treated with either 5 or 10 days of remdesivir.”
BackgroundImmunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”
Dioverti, M. V., Salto‐Alejandre, S., & Haidar, G. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00385-y · Cited by 79
Kusakabe, T., Lin, W.-Y., Cheong, J., Singh, G., Ravishankar, A., Yeung, S. T., Mesko, M., DeCelie, M. B., Carriche, G. M., Zhao, Z., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01637-4 · Cited by 81
Artificial intelligence, drug repurposing and peer review
Levin, J. M., Oprea, T. I., Davidovich, S., Clozel, T., Overington, J. P., Vanhaelen, Q., Cantor, C. R., Bischof, E., & Zhavoronkov, A. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0686-x · Cited by 79
Horowitz, R. I., & Freeman, P. R. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109851 · Cited by 79
Wang, Z., & Yang, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01013 · Cited by 79
Kumar, N., Awasthi, A., Kumari, A., Sood, D., Jain, P., Singh, T., Sharma, N., Grover, A., & Chandra, R. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1808072 · Cited by 79
COVID-19—Lessons Learned and Questions Remaining
Fang, F. C., Benson, C. A., del Río, C., Edwards, K. M., Fowler, V. G., Fredricks, D. N., Limaye, A. P., Murray, B. E., Naggie, S., Pappas, P. G., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1654 · Cited by 78
Repurposing drugs for the management of COVID-19
Cusinato, J., Cau, Y., Calvani, A. M., & Mori, M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1861248 · Cited by 78
Manipulation of ACE2 expression in COVID-19
Chaudhry, F., Lavandero, S., Xie, X., Sabharwal, B., Zheng, Y., Correa, A. A., Narula, J., & Levy, P. D. (2020) · Open Heart · doi:10.1136/openhrt-2020-001424 · Cited by 83
Al‐Abdouh, A., Bizanti, A., Barbarawi, M., Jabri, A., Kumar, A., Fashanu, O. E., Khan, S. U., Zhao, D., Antar, A. A. R., & Michos, E. D. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106272 · Cited by 79
The race for antiviral drugs to beat COVID — and the next pandemic
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-00958-4 · Cited by 79
Butler, C., Yu, L., Dorward, J., Gbinigie, O. A., Hayward, G., Saville, B. R., van Hecke, O., Berry, N., Detry, M. A., Saunders, C. T., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00310-6 · Cited by 82
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling
Zizzo, G., Tamburello, A., Castelnovo, L., Laria, A., Mumoli, N., Faggioli, P. M., Stefani, I., & Mazzone, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795315 · Cited by 78
Schäfer, A., Martinez, D. R., Won, J. J., Meganck, R. M., Moreira, F. R., Brown, A. J., Gully, K. L., Zweigart, M. R., Conrad, W. S., May, S. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3410 · Cited by 100
Gelman, R., Bayatra, A., Kessler, A., Schwartz, A., & Ilan, Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1776161 · Cited by 81
Dissecting the interaction between COVID‐19 and diabetes mellitus
Chee, Y. J., Tan, S. K., & Yeoh, E. C. K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13326 · Cited by 82
Animal models for SARS‐CoV‐2 research: A comprehensive literature review
Pandey, K., Acharya, A., Mohan, M., Ng, C. L., Reid, S. P., & Byrareddy, S. N. (2020) · Transboundary and Emerging Diseases · doi:10.1111/tbed.13907 · Cited by 82
The effects of wearing facemasks on oxygenation and ventilation at rest and during physical activity
Shein, S. L., Whitticar, S., Mascho, K., Pace, E., Speicher, R. H., & Deakins, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247414 · Cited by 78
Pavan, M., Bolcato, G., Bassani, D., Sturlese, M., & Moro, S. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1954919 · Cited by 81
COVID-19 pandemic: Its impact on liver disease and liver transplantation
Şahin, T. T., Akbulut, S., & Yılmaz, S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i22.2987 · Cited by 77
Remdesivir for Adults With COVID-19
Wilt, T. J., Kaka, A. S., MacDonald, R. H., Greer, N. L., Obley, A. J., & Duan‐Porter, W. (2020) · Annals of Internal Medicine · doi:10.7326/m20-5752 · Cited by 77
Piovani, D., Christodoulou, M. N., Hadjidemetriou, A., Pantavou, K. G., Zaza, P. N., Bagos, P. G., Bonovas, S., & Nikolopoulos, G. K. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.11.033 · Cited by 78
Padhi, A. K., Shukla, R., Saudagar, P., & Tripathi, T. (2020) · iScience · doi:10.1016/j.isci.2020.101992 · Cited by 77
Zhuravel, S. V., Khmelnitskiy, O., Burlaka, O. O., Gritsan, A. I., Goloshchekin, B. M., Kim, S., & Hong, K. Y. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101169 · Cited by 77
ACTIV-3/TICO Bamlanivimab Study Group*, Lundgren, J. D., Grund, B., Barkauskas, C. E., Holland, T. L., Gottlieb, R., Sandkovsky, U., Brown, S. M., Knowlton, K. U., Self, W. H., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3507 · Cited by 78
Polizzotto, M. N., Nordwall, J. A., Babiker, A. G., Phillips, A., Vock, D. M., Eriobu, N., Kwaghe, V., Paredes, R., Mateu, L., Ramachandruni, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00101-5 · Cited by 78
Tan, B. W. L., Tan, B. W. Q., Tan, A. L. M., Schriver, E., Gutiérrez‐Sacristán, A., Das, P., Yuan, W., Hutch, M. R., Barrio, N. G., Pedrera‐Jiménez, M., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101724 · Cited by 77
Hirotsu, Y., Kobayashi, H., Kakizaki, Y., Saito, A., Tsutsui, T., Kawaguchi, M., Shimamura, S., Hata, K., Hanawa, S., Toyama, J., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.001 · Cited by 77
COVID-19 Therapeutic Options Under Investigation
Kaddoura, M., Ibrahim, M. A., Hijazi, G., Soudani, N., Audi, A., Alkalamouni, H., Haddad, S., Eid, A. H., & Zaraket, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01196 · Cited by 75
Pharmacogenomics of COVID-19 therapies
Takahashi, T., Luzum, J. A., Nicol, M. R., & Jacobson, P. A. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-00143-y · Cited by 76
Benkeser, D. C., Diaz, I. M., Luedtke, A. R., Segal, J. B., Scharfstein, D. O., & Rosenblum, M. (2020) · Biometrics · doi:10.1111/biom.13377 · Cited by 83
Tackling COVID‐19 Using Remdesivir and Favipiravir as Therapeutic Options
Obireddy, S. R., & Lai, W. (2020) · ChemBioChem · doi:10.1002/cbic.202000595 · Cited by 76
Food‐derived antioxidants and COVID‐19
Lammi, C., & Arnoldi, A. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13557 · Cited by 77
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies
Calabretta, E., Moraleda, J. M., Iacobelli, M., Jara, R., Vlodavsky, I., O’Gorman, P., Pagliuca, A., Mo, C. C., Baron, R. M., Aghemo, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17240 · Cited by 75
Reynolds, D., Huesemann, M. H., Edmundson, S. J., Sims, A. M., Hurst, B. L., Cady, S. L., Beirne, N., Freeman, J., Berger, A., & Gao, S. (2021) · Algal Research · doi:10.1016/j.algal.2021.102331 · Cited by 78
Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display
Norman, A. R., Franck, C., Christie, M., Hawkins, P. M. E., Patel, K., Ashhurst, A. S., Aggarwal, A., Low, J. K. K., Siddiquee, R., Ashley, C. L., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01708 · Cited by 76
Recent advances in developing small-molecule inhibitors against SARS-CoV-2
Xiang, R., Yu, Z., Wang, Y., Wang, L., Huo, S., Li, Y., Liang, R., Hao, Q., Ying, T., Gao, Y., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.016 · Cited by 77
Surface Glycan Modification of Cellular Nanosponges to Promote SARS-CoV-2 Inhibition
Ai, X., Wang, D., Honko, A. N., Duan, Y., Gavrish, I., Fang, R. H., Griffiths, A., Gao, W., & Zhang, L. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07798 · Cited by 76
Walz, L., Cohen, A. J., Rebaza, A. P., Vanchieri, J., Slade, M. D., Dela Cruz, C. S., & Sharma, L. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-020-05730-z · Cited by 82
Nanomedicine as A Promising Approach For Diagnosis, Treatment and Prophylaxis Against COVID-19
Ellah, N. H. A., Gad, S. F., Muhammad, K., Batiha, G. E., & Hetta, . F. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0247 · Cited by 75
Bain, R., Cosgriff, R., Zampoli, M., Elbert, A., Burgel, P., Carr, S. B., Castaños, C., Colombo, C., Corvol, H., Faro, A., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.11.021 · Cited by 75
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
Bartoli, A., Gabrielli, F., Alicandro, T., Nascimbeni, F., & Andreoné, P. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02569-9 · Cited by 74
Nardelli, C., Gentile, I., Setaro, M., Domenico, C. D., Pinchera, B., Buonomo, A. R., Zappulo, E., Scotto, R., Scaglione, G. L., Castaldo, G., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.625581 · Cited by 75
Sex and gender differences in COVID-19: More to be learned!
Ya’qoub, L., Elgendy, I. Y., & Pepine, C. J. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100011 · Cited by 80
COVID-19 and Acute Kidney Injury
Hilton, J., Boyer, N., Nadim, M. K., Forni, L. G., & Kellum, J. A. (2022) · Critical Care Clinics · doi:10.1016/j.ccc.2022.01.002 · Cited by 81
Pregnancy and COVID ‐19: pharmacologic considerations
D'Souza, R. D., Ashraf, R., Rowe, H., Zipursky, J. S., Clarfield, L., Maxwell, C. V., Arzola, C., Lapinsky, S. E., Paquette, K., Murthy, S., et al. (2020) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.23116 · Cited by 80
Francés‐Monerris, A., Hognon, C., Miclot, T., García‐Iriepa, C., Iriepa, I., Terenzi, A., Grandemange, S., Barone, G., Marazzi, M., & Monari, A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00779 · Cited by 72
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
Aleissa, M. M., Silverman, E. A., Acosta, L. M. P., Nutt, C. T., Richterman, A. G., & Marty, F. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01814-20 · Cited by 74
Strohbehn, G. W., Heiss, B. L., Rouhani, S. J., Trujillo, J., Yu, J., Kacew, A. J., Higgs, E. F., Bloodworth, J. C., Cabanov, A., Wright, R. C., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2117 · Cited by 76
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Camprubí-Ferrer, D., Almuedo-Riera, A., Martí-Soler, H., Soriano, À., Hurtado, J. C., Subirà, C., Grau-Pujol, B., Krolewiecki, A. J., & Muñóz, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242184 · Cited by 74
Effectiveness of Natural Antioxidants against SARS-CoV-2? Insights from the In-Silico World
Rehman, M. F. U., Akhter, S., Batool, A. I., Selamoğlu, Z., Sevindik, М., Eman, R., Mustaqeem, M., Akram, M. S., Kanwal, F., Lu, C., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10081011 · Cited by 77
Metadata
- Authors
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M.-D., Ruiz-Palacios, G. M., Benfield, T., Fätkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren, J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S., & Lane, H. C.
- Affiliations
- National Institutes of Health (US)
- From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) — all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical...
- Corresponding author
- Beigel, John H.
- ORCID
- Beigel, John H.
- Dodd, Lori E.
- Mehta, Aneesh K.
- Zingman, Barry S.
- Kalil, Andre C.
- Hohmann, Elizabeth
- Chu, Helen Y.
- Luetkemeyer, Annie
- Kline, Susan
- Finberg, Robert W.
- Dierberg, Kerry
- Tapson, Victor
- Patterson, Thomas F.
- Paredes, Roger
- Short, William R.
- Touloumi, Giota
- Lye, David Chien
- Ohmagari, Norio
- Oh, Myoung-don
- Ruiz-Palacios, Guillermo M.
- Benfield, Thomas
- Fätkenheuer, Gerd
- Atmar, Robert L.
- Creech, C. Buddy
- Lundgren, Jens
- Babiker, Abdel G.
- Pett, Sarah
- Neaton, James D.
- Burgess, Timothy H.
- Bonnett, Tyler
- Makowski, Mat
- Nayak, Seema
- Lane, H. Clifford
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-05
- Volume
- 383
- Issue
- 19
- Pages
- 1813-1826
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7262788
- OpenAlex
- W3027630905
- Cited by
- 7,267
- References
- 22
- Citations by year
- 2026: 146 · 2025: 324 · 2024: 518 · 2023: 901 · 2022: 1447 · 2021: 2475 · 2020: 1451
- FWCI
- 206.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- eScholarship@McGill (McGill) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Cancer Institute (HHSN261200800001E, HHSN261201500003I)
- National Institute of Allergy and Infectious Diseases (UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148575, UM1AI148576, UM1AI148684, UM1AI148685, UM1AI148689)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Keywords
- remdesivir, COVID-19 pandemic, SARS-CoV-2, antiviral therapy, hospitalized patients, lower respiratory tract infection, time to recovery, mortality, serious adverse events, clinical improvement, treatment efficacy, SARS-CoV-2 RNA load, viral load reduction, disease severity, prognostic factors, prognostic score
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adenosine Monophosphate, Adult, Aged, Alanine, Antiviral Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxygen Inhalation Therapy, Pneumonia, Viral, Respiration, Artificial, Time Factors, Extracorporeal Membrane Oxygenation, Coronavirus Infections, Kaplan-Meier Estimate, Young Adult, Pandemics, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
